Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA.
Department of Pathology, Massachusetts General Hospital, Boston, MA.
Am J Surg Pathol. 2020 Jul;44(7):881-892. doi: 10.1097/PAS.0000000000001489.
In follicular thyroid neoplasms without invasion, a diagnosis of atypical adenoma (AA) (follicular tumor of uncertain malignant potential) may be rendered if atypical features (indefinite capsular/vascular invasion, necrosis, solid growth, increased mitoses) are present. This study compares clinical, histologic, and molecular features of patients with AAs (n=31), nonmetastatic follicular thyroid carcinoma (nmFTC) (n=18), and metastatic follicular thyroid carcinoma (mFTC) (n=38). Patients with mFTC were older. Mitotic activity in areas of solid growth was greatest in mFTC (P=0.05). Oncocytic tumors tended to show solid growth (P=0.04). The presence or frequency of capsular and/or vascular invasion was not different between nmFTC and mFTC. TERT promoter mutations were higher in patients with mFTC (50%) than nmFTC (25%) and AA (10%) (P=0.02). TERT promoter mutation was associated with necrosis (P=0.01) and solid growth plus increased mitoses (P=0.03). Necrosis and TERT promoter mutations were identified in all groups, most frequently in mFTC. The combination of solid growth with increased mitoses, necrosis, and TERT promoter mutation was only seen in follicular carcinomas. Poorly differentiated features, vascular invasion, and TERT promoter mutation correlated with metastasis in FTC. Given the low frequency of necrosis and TERT promoter mutation in AAs, close clinical follow-up is recommended in patients with these findings, especially if additional atypical features (such as solid growth plus mitoses) are present.
在无侵袭性滤泡甲状腺肿瘤中,如果存在非典型特征(不确定的包膜/血管侵袭、坏死、实性生长、核分裂增多),可以诊断为非典型腺瘤(AA)(滤泡肿瘤恶性潜能不确定)。本研究比较了 31 例 AA 患者、18 例非转移性滤泡甲状腺癌(nmFTC)患者和 38 例转移性滤泡甲状腺癌(mFTC)患者的临床、组织学和分子特征。mFTC 患者年龄较大。实性生长区的有丝分裂活性在 mFTC 中最大(P=0.05)。嗜酸细胞肿瘤往往表现为实性生长(P=0.04)。nmFTC 和 mFTC 之间包膜和/或血管侵袭的存在或频率没有差异。TERT 启动子突变在 mFTC 患者(50%)中高于 nmFTC(25%)和 AA(10%)(P=0.02)。TERT 启动子突变与坏死(P=0.01)和实性生长伴核分裂增多(P=0.03)相关。所有组均存在坏死和 TERT 启动子突变,在 mFTC 中最常见。实性生长伴核分裂增多、坏死和 TERT 启动子突变的组合仅见于滤泡癌。低分化特征、血管侵袭和 TERT 启动子突变与 FTC 的转移相关。鉴于 AA 中坏死和 TERT 启动子突变的频率较低,建议对有这些发现的患者进行密切的临床随访,特别是如果存在其他非典型特征(如实性生长伴核分裂增多)。